Page 8 - Flipbook
P. 8
Module Overview
Module I Module II Module III Module IV
DNA Damage Response in The Intersection of Germline and Advanced Prostate Cancer: PARP Inhibitors for Advanced
Prostate Cancer: Therapeutic Somatic Genetic Testing in A Review of the Data for Prostate Cancer: Adverse Event
Implications Advanced Prostate Cancer PARP Inhibitors Management
• Evolution and overview of • • • Timing, monitoring, and
treatment options for Diagnostic implications of Mechanisms of action of management of adverse
DDR mutations
prostate cancer PARP inhibitors for prostate
cancer with DDR mutations events with PARP inhibitors
• Mutations and DNA damage • Genetic testing (who to test, • Clinical trials of PARP • Uncommon, but important,
response (DDR) genes in what genes, and how should inhibitors in mCRPC with DDR toxicities reported with PARP
prostate cancer testing be done) mutations inhibitors
• DDR pathways and their • Importance of genetic
therapeutic implications counselling
DDR, DNA damage response; mCRPC, metastatic castration-resistant prostate cancer; PARP, poly(ADP-ribose) polymerase
